Ftse Mib
34.713,36
1,09%
DAX
18.789,53
0,59%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.883,46
-0,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL) Notizie

MDGL

Madrigal Pharmaceuticals (MDGL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MDGL
DataOraFonteTitoloSimboloCompagnia
07/05/202422:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202422:34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202422:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202415:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
24/04/202422:00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
23/04/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
16/04/202422:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
09/04/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
19/03/202404:58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
18/03/202421:04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/03/202412:30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/03/202421:15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
05/03/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202413:01GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202413:00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202412:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/02/202420:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
08/02/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of MedicineNASDAQ:MDGLMadrigal Pharmaceuticals Inc
29/01/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Additions to Its Leadership TeamNASDAQ:MDGLMadrigal Pharmaceuticals Inc
26/01/202400:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
04/01/202414:00GlobeNewswire Inc.Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
03/01/202422:30GlobeNewswire Inc.Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
13/12/202322:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
22/11/202323:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
21/11/202314:00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
10/11/202314:00GlobeNewswire Inc.Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver HealthNASDAQ:MDGLMadrigal Pharmaceuticals Inc
10/11/202313:30GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/11/202314:00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
02/11/202321:05GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MDGL

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
NEXI
Nexi S.p.A
BIT
BFF
BFF Bank
BIT
BPE
Bper Banca
BIT
MB
Mediobanca Banca di Cred...
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
G
Generali
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network